Doxaprost is an orally active bronchodilator. Doxaprost was 73 and 32 times more potent that (+/-) 11-deoxy PGE1 by the aerosol and i.v. routes, respectively. Doxaprost also demonstrated a longer duration of effect. Doxaprost is indicated for the treatment of symptoms of benign prostatic hyperplasia and hypertension. Common side effects are: dizziness, weakness and rarely fainting, especially at the beginning of the medication use. Doxaprost potentiates the action of lowering the blood pressure of other alpha-blockers and anti-hypertensives.

THIOINOSINE (Methylmercaptopurine riboside, NSC- 40774) is a purine derivative with antineoplastic and anti-angiogenic properties. THIOINOSINE is readily converted in cells to its active form, 6-methylmercaptopurine ribonucleoside 5'- monophosphate (MMPR-P), by the enzyme adenosine kinase. THIOINOSINE inhibits amidophosphoribosyltransferase, the first committed step in de novo purine synthesis, and inhibits fibroblast growth factor-2 (FGF2)-induced cell proliferation. It has been used similarly to Mercaptopurine in the treatment of Leukemia. It has being tested in clinical trials for advanced pancreatic cancer.

Viprostol (also known as CL115,347), a prostaglandin E2 congener that was studied as an antihypertensive agent. Viprostol has a potent and prolonged blood pressure lowering effect in many models of hypertension. In clinical studies, viprostol has been demonstrated to lower arterial blood pressure significantly in man following transdermal and/or intravenous administration. The antihypertensive action of viprostol has been suggested to be the result of peripheral vasodilatation. In addition, the drug participated in a clinical trial in normal subjects and in patients with Raynaud's phenomenon. It was found the optimal dosage was 1000 ug; the effect could last for 84 hours; higher dosage may be associated with a "steal" phenomenon.

Apadenoson (BMS-068645) is a selective adenosine 2A agonist that contains a methyl ester group which undergoes esterase hydrolysis to its acid metabolite. Apadenoson had been in phase III clinical trials by Forest (now a part of Allergan) for the treatment of coronary artery disease. However, this study has been terminated.

Asulacrine, also known as CI-921, an inhibitor of topoisomerase II, participated in clinical trials phase II for the treatment of cancer. In spite of the positive and promising results, this drug showed the toxicity, phlebitis that blocks its implementation in the future.

Cicortonide is a synthetic cyano-glucocorticoid with anti-inflammatory and antirheumatic, as well as antiallergenic properties.

Xanoxic acid was developed as a bronchodilator that has never been marketed. Information about the current use of this agent is not available.

Becanthone is an antischistosomal agent possesses the ability to inhibit tumors.

Clopipazan (SKF-69634) is an antipsychotic drug related to thioxanthenes. Quantitative pharmaco-EEG analyses showed systematic effects on human brain function with doses as low as 10 mg. In the early phase 2 clinical studies on chronic schizophrenic patients, however, the drug appeared to have a slow onset of action and weak neuroleptic potency.